Kestra Medical Technologies (KMTS) has just posted its latest quarterly update with Q2 2026 revenue of US$22.6 million and a basic EPS loss of US$0.64, alongside a trailing 12 month EPS loss of US$3.44 on revenue of US$74.3 million that highlights the current earnings profile. The company has seen quarterly revenue move from US$14.7 million in Q2 2025 to US$22.6 million in Q2 2026. Over the same period, quarterly basic EPS losses have shifted from US$1.19 in Q2 2025 to US$0.64 in Q2 2026, setting up an earnings season story where revenue trends are being weighed against ongoing losses and the pressure this puts on margins.

See our full analysis for Kestra Medical Technologies.

With the headline numbers set, the next step is to see how this mix of revenue growth potential, continuing losses and margin pressure lines up with the main narratives around Kestra Medical Technologies and where those stories might need updating.

US$74.3m trailing revenue against US$138.8m loss

• On a trailing 12 month basis to Q2 2026, Kestra generated US$74.3 million of revenue and reported a net loss of US$138.8 million, which gives a sense of how far expenses currently sit above the top line.
• Consensus narrative points to forecast revenue growth of about 32.2% a year, and this growth focus sits against the reality that trailing losses have averaged 22.3% growth a year. Investors are being asked to weigh faster expected revenue expansion against a history of widening losses.
  • Supporters highlight that revenue forecasts are well above the cited US market growth rate of 10.5%, yet trailing net loss of US$138.8 million on US$74.3 million revenue shows that profitability is still some distance away.
  • What stands out is that analysts also expect the company to remain unprofitable over the next three years, which means the growth story is currently centred on sales rather than earnings improvement.

Bulls often focus on how this sales profile could evolve into a more profitable business, so it is worth checking how that case is framed in detail. 🐂 Kestra Medical Technologies Bull Case

Premium 15.4x P/S versus peers at 10.2x

• The shares trade on a trailing P/S of 15.4x, compared with a peer average of 10.2x and the wider US Medical Equipment industry at 2.8x. This highlights that the market is currently assigning a premium to Kestra’s revenue base.
• Bears argue that paying a higher multiple only makes sense if revenue growth and margins eventually justify it, and the current combination of unprofitable trailing results and no forecast path to profitability within three years tests that view.
  • Critics highlight that the company remains loss making on a trailing basis, with US$138.8 million of net loss against US$74.3 million of revenue, while the premium P/S multiple already prices in strong expectations.
  • What is challenging for the bearish view is that analyst targets still imply upside to US$29.00 from the current US$19.58 share price. This suggests some market participants see enough potential growth to support that premium.

Skeptics point to the rich 15.4x P/S and ongoing losses as key reasons for caution, so a closer look at the bear case can help you stress test your own assumptions. 🐻 Kestra Medical Technologies Bear Case

Analyst upside to US$29.00 despite ongoing EPS losses

• Analysts in aggregate see a target price of US$29.00 compared with the current US$19.58 share price, while trailing basic EPS over the last 12 months sits at a loss of US$3.44. This shows that expectations are being set well ahead of reported earnings.
• Consensus narrative suggests that faster forecast revenue growth of about 32.2% a year and the potential for margins to improve over time are key reasons behind that implied upside, even though analysts are not forecasting profitability within the next three years.
  • Supporters point to the revenue growth forecasts and industry comparisons to argue that the company could eventually close some of the gap between US$3.44 of EPS loss and the earnings level implied by those targets.
  • At the same time, the combination of a premium 15.4x P/S multiple and a trailing net loss of US$138.8 million means the numbers also highlight how much execution is already reflected in that US$29.00 target.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Kestra Medical Technologies on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Mixed messages in the numbers or a clear story taking shape? If you want to move fast and ground your own view in the details, start by weighing the 2 key rewards and 1 important warning sign.

Explore Alternatives

Kestra Medical Technologies combines a premium 15.4x P/S multiple with US$138.8 million of trailing net loss and no analyst forecast for profitability within three years.

If you are uneasy about paying up for losses and want ideas where valuation and fundamentals look more grounded, start comparing opportunities using the 50 high quality undervalued stocks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.